William Blair Brokers Boost Earnings Estimates for SPRY

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) – Equities research analysts at William Blair raised their Q4 2025 EPS estimates for shares of ARS Pharmaceuticals in a research note issued to investors on Wednesday, November 13th. William Blair analyst L. Hanbury-Brown now expects that the company will post earnings of $0.05 per share for the quarter, up from their previous estimate of $0.02. William Blair currently has a “Strong-Buy” rating on the stock. The consensus estimate for ARS Pharmaceuticals’ current full-year earnings is ($0.64) per share.

SPRY has been the subject of a number of other research reports. Raymond James upgraded shares of ARS Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and increased their price objective for the company from $18.00 to $22.00 in a research note on Tuesday, August 13th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $30.00 price target on shares of ARS Pharmaceuticals in a report on Tuesday, October 8th. Finally, Leerink Partners boosted their price objective on shares of ARS Pharmaceuticals from $21.00 to $25.00 and gave the stock an “outperform” rating in a research report on Friday, September 20th. Four investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $24.00.

ARS Pharmaceuticals Stock Up 0.2 %

ARS Pharmaceuticals stock opened at $14.11 on Friday. The business has a 50 day moving average price of $14.58 and a two-hundred day moving average price of $11.67. ARS Pharmaceuticals has a 12 month low of $4.27 and a 12 month high of $18.51.

Hedge Funds Weigh In On ARS Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC acquired a new position in shares of ARS Pharmaceuticals during the 1st quarter worth about $119,000. Russell Investments Group Ltd. bought a new position in shares of ARS Pharmaceuticals during the first quarter worth approximately $60,000. Vanguard Group Inc. boosted its stake in ARS Pharmaceuticals by 37.0% in the 1st quarter. Vanguard Group Inc. now owns 2,886,455 shares of the company’s stock valued at $29,500,000 after purchasing an additional 779,969 shares during the period. Public Employees Retirement System of Ohio acquired a new position in ARS Pharmaceuticals in the 1st quarter valued at $172,000. Finally, Paloma Partners Management Co bought a new position in ARS Pharmaceuticals during the 1st quarter worth $103,000. Institutional investors own 68.16% of the company’s stock.

Insider Activity at ARS Pharmaceuticals

In other news, major shareholder James E. Flynn sold 528,456 shares of ARS Pharmaceuticals stock in a transaction on Monday, November 11th. The shares were sold at an average price of $18.04, for a total transaction of $9,533,346.24. Following the transaction, the insider now directly owns 5,274,735 shares of the company’s stock, valued at $95,156,219.40. This trade represents a 9.11 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Kathleen D. Scott sold 12,500 shares of the business’s stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $16.00, for a total transaction of $200,000.00. Following the completion of the transaction, the chief financial officer now directly owns 13,199 shares of the company’s stock, valued at $211,184. This trade represents a 48.64 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,584,351 shares of company stock worth $24,152,378. 40.10% of the stock is owned by insiders.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.